Annexin Pharmaceuticals - Public Comps and Valuation Multiples

Annexin Pharmaceuticals Overview

About Annexin Pharmaceuticals

Annexin Pharmaceuticals AB is a biotechnology company. It is developing biological drug candidate ANXV, a recombinant human protein Annexin A5 for treatment of various cardiovascular diseases. The company also focuses on development of ANXV for the treatment of retinal vein occlusion.

Founded

2014

HQ

Employees

Website

annexinpharma.com

Sectors

Drug Development & Therapeutics
Biopharmaceuticals
BioTech

Financials

LTM Revenue $48K

LTM EBITDA -$4.8M

EV

$11.2M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Annexin Pharmaceuticals Financials

As of December 2025, Annexin Pharmaceuticals reported last 12-month revenue of $48K and EBITDA of -$4.8M.

In the same period, Annexin Pharmaceuticals achieved -$4.8M in LTM net income.

See Annexin Pharmaceuticals valuation multiples based on analyst estimates

Annexin Pharmaceuticals P&L

In the most recent fiscal year, Annexin Pharmaceuticals reported EBITDA of -$5.5M.

Annexin Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Annexin Pharmaceuticals valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue	$48K	XXX	n/a	XXX	XXX	XXX
Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
Gross Margin	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA	-$4.8M	XXX	-$5.5M	XXX	XXX	XXX
EBITDA Margin	-10160%	XXX	n/a	XXX	XXX	XXX
EBIT	-$4.8M	XXX	-$5.5M	XXX	XXX	XXX
EBIT Margin	-10160%	XXX	n/a	XXX	XXX	XXX
Net Profit	-$4.8M	XXX	-$5.5M	XXX	XXX	XXX
Net Margin	-10160%	XXX	n/a	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Annexin Pharmaceuticals including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $48K. EBITDA for the last twelve months was -$4.8M.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2026)	Next Fiscal Year (2027)	Two Years Forward (2028)
Total Revenue	$48K	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	n/a	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	n/a	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	-$4.8M	Analyst estimates available to subscribers	-$5.5M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	-10159.6% EBITDA margin	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	-$4.8M	Analyst estimates available to subscribers	-$5.5M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	-10159.6% EBIT margin	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	-$4.8M	Analyst estimates available to subscribers	-$5.5M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	-10159.6% net profit margin	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Annexin Pharmaceuticals

This financial data table provides comprehensive performance metrics for Annexin Pharmaceuticals, a company based in Sweden. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Annexin Pharmaceuticals generated $48K in revenue over the last twelve months.
The company achieved -$4.8M in EBITDA over the last twelve months.
Net income over the last twelve months reached -$4.8M.

Fiscal Year Performance

Fiscal year EBITDA was -$5.5M.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Annexin Pharmaceuticals. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Annexin Pharmaceuticals Stock Performance

Annexin Pharmaceuticals has current market cap of SEK 140M (or $15.2M), and EV of SEK 103M (or $11.2M).

Market Cap Evolution

Annexin Pharmaceuticals Stock Data

As of January 2, 2026, Annexin Pharmaceuticals's stock price is SEK 20 (or $2).

See Annexin Pharmaceuticals trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$11.2M	$15.2M	XXX	XXX	XXX	XXX	n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Annexin Pharmaceuticals Valuation Multiples

Annexin Pharmaceuticals's trades at n/a EV/Revenue multiple, and -2.3x EV/EBITDA.

See valuation multiples for Annexin Pharmaceuticals and 15K+ public comps

Annexin Pharmaceuticals Financial Valuation Multiples

As of January 2, 2026, Annexin Pharmaceuticals has market cap of $15.2M and EV of $11.2M.

Equity research analysts estimate Annexin Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Annexin Pharmaceuticals has a P/E ratio of -3.1x.

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Market cap (current)	$15.2M	XXX	$15.2M	XXX	XXX	XXX
EV (current)	$11.2M	XXX	$11.2M	XXX	XXX	XXX
EV/Revenue	235.3x	XXX	n/a	XXX	XXX	XXX
EV/EBITDA	-2.3x	XXX	-2.3x	XXX	XXX	XXX
EV/EBIT	-2.3x	XXX	-2.3x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	-3.1x	XXX	-3.1x	XXX	XXX	XXX
EV/FCF	n/a	XXX	-2.0x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Annexin Pharmaceuticals Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Annexin Pharmaceuticals Margins & Growth Rates

Annexin Pharmaceuticals's last 12 month revenue growth is 18050%

Annexin Pharmaceuticals's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.1M for the same period.

Annexin Pharmaceuticals's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Annexin Pharmaceuticals's rule of X is 34965% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Annexin Pharmaceuticals and other 15K+ public comps

Annexin Pharmaceuticals Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue Growth	18050%	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	-10160%	XXX	n/a	XXX	XXX	XXX
EBITDA Growth	-153%	XXX	n/a	XXX	XXX	XXX
Rule of 40	n/a	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	34965%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$1.1M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	n/a	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial